Mass Spectrometry is key technology for studying critical molecules and pathways. Defining molecular targets is crucial for the process of drug development.
In our group, we are focused on using proteomics, mass spectrometry and biochemical approaches to understand disease processes.
The group has expertise in proteomics based methodologies and hosts a platform containing a variety of chromatography equipment and mass spectrometers.
Kessler Group Sky Garden London Nov 2018
- For Non-Scientists
- Research Overview
- Mass Spectrometry
- Public Engagement
- Photo Gallery
- Virtual tour of the Kessler Lab
- Former Group Members
The Bloom syndrome complex senses RPA-coated single-stranded DNA to restart stalled replication forks
Shorrocks A-MK. et al, (2021), Nature Communications, 12
Inflammasome activation controlled by the interplay between post-translational modifications: emerging drug target opportunities
Liang Z. et al, (2021), Cell Communication and Signaling, 19
Global proteomic analysis of extracellular matrix in mouse and human brain highlights relevance to cerebrovascular disease.
Pokhilko A. et al, (2021), J Cereb Blood Flow Metab
The deubiquitylase USP9X controls ribosomal stalling.
Clancy A. et al, (2021), The Journal of cell biology, 220
DUB esterase activity further decodes ubiquitin’s enigma
Kessler BM., (2021), Proceedings of the National Academy of Sciences, 118, e2026389118 - e2026389118